NASDAQ$TRML

Tourmaline Bio Inc · Q2 2023 earnings

Q2 2023 earnings · · Investor relations

Headline financials

Total Revenue

$0.00

No prior period
EPS (adj)

-$3.50

Previous: -$4.40+20.5%
R&D Expenses

$14.5M

No prior period
G&A Expenses

$1.92M

No prior period
Capital Expenditures

-$221K

Previous: $1.09M-120.2%
Free Cash Flow

-$14.9M

Previous: -$18.4M+18.9%
Net Income

-$14.7M

Previous: -$18.1M+18.6%
Operating Income

-$10.1M

Previous: -$18.4M+45.1%
Gross Profit

-$261K

No prior period
Cash & Equivalents

$152M

Previous: $25.5M+496.6%
Total Assets

$159M

Previous: $221M-28.0%
R&D Expense

$4.09M

No prior period
Stock-Based Comp

$4.44M

Previous: $2.85M+56.0%

Revenue & EPS history

Tourmaline Bio · Revenue · Quarterly

$0

Q2 2023

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports

Historical avg

+0.7%

Avg return

Earnings day

-5.0%

Avg return

5 days after

+13.7%

Avg return

30 days after

59%

10 / 17 earnings

Positive

+11.6%

Q4 2023

Best reaction

-9.7%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025+3.8%+3.1%+122.3%
Q1 2025+4.6%+9.9%+26.5%
Q4 2024-2.8%-4.8%-1.4%
Q3 2024+5.0%-4.9%-5.6%
Q2 2024+2.0%+4.6%+12.2%
Q1 2024-0.6%-4.8%+2.6%
Q4 2023+11.6%-38.1%-60.9%
Q3 2023-1.2%
Q2 2023+1.3%
Q1 2023-8.0%
Q4 2022+2.8%
Q3 2022+7.0%
Q2 2022-9.7%
Q1 2022+3.1%
Q4 2021+4.6%
Q3 2021-7.0%
Q2 2021-5.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro